

Personalized Therapy Requires Rigor in Biomarker Performance



Debu Tripathy

Debu Tripathy, MD
Editor-in-Chief

Personalized medicine is all about tailoring therapy based on clinical and biomarker characteristics, allowing us to derive the most focused benefit/risk ratio. Early successes in personalized medicine were seen as early as the 1960s as cytogenetics provided a basis for classifying leukemias, the identification of estrogen receptors in some breast cancers, and in the mid-1980s, the demonstration that amplification and overexpression of the *HER2* gene that encoded a growth factor receptor was associated with a worse outcome.¹ This culminated in early trials showing that the humanized anti-*HER2* antibody trastuzumab was effective against *HER2*-overexpressing breast cancer.^{2,3}

This issue of *The American Journal of Hematology/Oncology*[®], Dr Press and colleagues affirm that when it comes to biomarkers, the devil is in the details. Nearly 20 years after the approval of trastuzumab, there remains controversy and shifting criteria for the use of fluorescence in situ hybridization (FISH) to define *HER2* amplification status and on this basis to recommend *HER2*-targeted therapy, which impacts survival in early and advanced breast cancer. Although the genome guides the expression of proteins, it is proteins that ultimately drive biology. In the case of the estrogen receptor, protein expression is mediated by transcriptional control and not gene copy number. In the case of *HER2*, it is mostly the opposite case—protein expression levels are guided by gene copy number. However, a confounding factor is that amplifications tend to involve large segments of, or even, the entire chromosomes. Probes must be large enough to be visible, so it is necessary for them to span several genes. It is also necessary to normalize gene copy number to chromosome copy number, typically assessed by probing the chromosome centromere (CEP), over an area that also encompasses several genes. The relationship between gene copy number and expression varies not only for specific genes, but possibly among cases for a given gene, so it is critical to develop a robust body of data to formulate a reliable assay.

In this article, actual observed outcomes on the basis of assay results with the targeted therapy in question, the ultimate proof for the utility of biomarkers and their thresholds for positivity, are provided for the categories of controversy that include the “equivocal” category for gene amplification based on FISH assays. Because the *HER2/CEP17* ratio (≥ 2.0 for positivity) was used for the basis of the trials described in this article, it was possible to describe the outcomes of the equivocal group, representing nearly 5% of all cases. Please read this important article for the punchline—it may influence your opinion on the ongoing controversy regarding the guidelines for interpreting *HER2* results—the underpinning for the use of *HER2*-targeted therapy and its clear clinical benefits.

References

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the *HER-2/neu* oncogene. *Science*. 1987;235(4785):177-182.
2. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185*HER2* monoclonal antibody in patients with *HER2/neu*-overexpressing metastatic breast cancer. *J Clin Oncol*. 1996;14(3):737-744.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against *HER2* for metastatic breast cancer that overexpresses *HER2*. *N Engl J Med*. 2001;344(11):783-792.

EDITORIAL STAFF

Editor-in-Chief

Debu Tripathy, MD
Professor and Chair
Department of Breast Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, TX

Associate Editor

Jason J. Luke, MD, FACP
Assistant Professor of Medicine
University of Chicago
Chicago, IL

**Editorial Director
Oncology Specialty Group**
Silas Inman

Managing Editor

Anthony Berberabe, MPH
aberberabe@mjhassoc.com

Senior Art Director
Melissa Feinen

Editorial Offices

Physicians' Education Resource[®], LLC
2 Clarke Drive, Cranbury, NJ 08512
(609) 378-3701



President

Phil Talamo, CHCP

Vice President, Medical Affairs

Michael Perlmutter, PharmD, MS

General Manager

Michael Ball



Michael J. Hennessy Associates, Inc.

CORPORATE OFFICERS

Chairman and CEO

Michael J. Hennessy, Sr

Vice Chairman

Jack Lepping

President

Mike Hennessy, Jr

Chief Financial Officer

Neil Glasser, CPA/CFE

Executive Vice President,

Oncology Professional Relations

Donna Short

Chief Marketing Officer

Warren Dardine

Chief Digital Strategy Officer

Steve Ennen

Vice President of Editorial Services and Production

Kerrie Keegan

Vice President of Digital Media

Jung Kim

Chief Creative Officer

Jeff Brown

Vice President Live Events

Tom Tolve

Director of Human Resources

Shari Lundenberg